Rhythm Pharmaceuticals

RYTM

Market cap $5.78B

BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that seven presentations, including four late-breaking abstracts, have been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2026) taking place June 13-16, 2026 in Chicago.

BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the publication of a new, evidence-based consensus-driven diagnostic algorithm for Bardet-Biedl syndrome (BBS). “Streamlining Diagnosis of Bardet-Biedl Syndrome: New Diagnostic Algorithm with Updated Criteria,” was published in the peer-reviewed  American Journal of Medical Genetics.

BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, and Hunter Smith, Chief Financial Officer, will participate in fireside chats at two upcoming conferences.

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Bank of America Global Healthcare Conference 2026 Transcript

– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France –

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported better-than-expected first-quarter financial results on Tuesday.

BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that David Meeker, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Bank of America Global Healthcare Conference on Wednesday, May 13 at 3:00 p.m.

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.83 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.81 per share a year ago.

-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- First quarter 2026 net product revenue from global sales of IMCIVREE of $60.1 million -- -- IMCIVREE granted Marketing Authorization by European Commission for the treatment of obesity and control of hunger in patients with acquired hypothalamic obesity -- -- Japanese regulatory review of New Drug Application for setmelanotide to treat acquired hypothalamic obesity underway -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2026.